2. Search Result
Search Result
Results for "

myocardial failure

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

8

Peptides

1

Inhibitory Antibodies

4

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-142059
    PDE5-IN-4

    		Phosphodiesterase (PDE) Cardiovascular Disease Metabolic Disease
    PDE5-IN-4 is a phosphodiesterase 5 inhibitor. PDE5-IN-4 can be used for the research of acute myocardial infarction and damage caused by reperfusion, gastrointestinal diseases, damage caused by diabetes, and liver failure .
    PDE5-IN-4
  • HY-B0384
    Temocapril hydrochloride

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril hydrochloride
  • HY-100713
    Temocapril

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril
  • HY-B0592
    Trandolapril

    RU44570

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril
  • HY-114941
    Aladotril

    BP1137

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease
    Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .
    Aladotril
  • HY-116119
    BDF 9148

    		Sodium Channel Cardiovascular Disease
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .
    BDF 9148
  • HY-117715
    CK-3197

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-3197 is a weak inhibitor of Peak lll cyclic 3'5'-adenosine monophosphate phosphodiesterase (CAMP PDEl). CK-3197 has hemodynamic and myocardial energetic effects in vivo. CK-3197 is an imidazolone derivative used as a selective positive inotropic agent for congestive heart failure .
    CK-3197
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-B0592A
    Trandolapril hydrochloride

    RU44570 hydrochloride

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril hydrochloride
  • HY-100713R
    Temocapril (Standard)

    		Reference Standards Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril (Standard) is the analytical standard of Temocapril. This product is intended for research and analytical applications. Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases .
    Temocapril (Standard)
  • HY-B0592R
    Trandolapril (Standard)

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    Trandolapril (Standard)
  • HY-100713S
    Temocapril-d5

    		Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Temocapril-d5 is the deuterium labeled Temocapril. Temocapril is an angiotensin-converting enzyme (ACE) inhibitor. Temocapril hydrochloride can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases[1][2].
    Temocapril-d5
  • HY-162733
    SVC-02

    		Microtubule/Tubulin Cardiovascular Disease
    SVC-02 is a vasohibin (VASH) inhibitor with an IC50 value of 11 nM. SVC-02 reduces tubulin detyrosination. SVC-02 has the potential for the research of reduce myo-cardial stiffness and improve relaxation in Heart failure with preserved ejection fraction (HFpEF) .
    SVC-02
  • HY-163859
    LSD1-IN-33

    		Histone Demethylase Cardiovascular Disease
    LSD1-IN-33 (7d), an orally active LSD1 inhibitor with an IC50 of 4.51 nM, alleviates Ang II-induced NRCFs activation in vitro and reducing pathological myocardial remodeling in TAC-induced cardiac remodeling and heart failure in vivo .
    LSD1-IN-33
  • HY-112071A
    Prenalterol hydrochloride

    		Adrenergic Receptor Endocrinology
    Prenalterol hydrochloride is a partial adrenal agonist with functional β1-receptor specificity and positive inotropic effects. Prenalterol hydrochloride is effective in suppressing acute heart failure, low output syndrome after myocardial infarction, shock, and reducing orthostatic hypotension in Shy-Drager syndrome .
    Prenalterol hydrochloride
  • HY-B0251S
    Eplerenone-d3

    Epoxymexrenone-d3

    		 Mineralocorticoid Receptor Endogenous Metabolite Cardiovascular Disease
    Eplerenone-d3 is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC50 of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch[1][2].
    Eplerenone-d3
  • HY-N2037
    Higenamine
    3 Publications Verification

    Norcoclaurine; Demethyl-Coclaurine

    		 MAP3K MDM-2/p53 Adrenergic Receptor ROS Kinase Apoptosis Cardiovascular Disease Endocrinology
    Higenamine (Norcoclaurine), a β2-AR agonist with antioxidant capability, is a key component of the Chinese herb aconite root that prescribes for treating symptoms of heart failure in the oriental Asian countries. Higenamine is also a α1-adrenergic receptor antagonist with hypotensive effect. is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine protects myocyte Apoptosis and ischemia/reperfusion (I/R) injury through selective activation of beta2-adrenergic receptor (β2-AR). Higenamine also reduces I/R-induced myocardial infarction in mice. Higenamine can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .
    Higenamine
  • HY-P99645
    Goflikicept

    RPH 104

    		 Interleukin Related Cardiovascular Disease Inflammation/Immunology
    Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) .
    Goflikicept
  • HY-B1194
    Tetramisole hydrochloride

    (±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829

    		 Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole hydrochloride
  • HY-B1194A
    Tetramisole

    		Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole
  • HY-B0592S2
    rac-Trandolapril-d5

    rac-RU44570-d5

    		 Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    rac-Trandolapril-d5 (rac-RU44570-d5) is deuterium labeled Trandolapril. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .
    rac-Trandolapril-d5
  • HY-N0107
    Cyclovirobuxine D

    		Apoptosis Autophagy mTOR Akt Cardiovascular Disease
    Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .
    Cyclovirobuxine D
  • HY-142698
    SGC agonist 2

    		Guanylate Cyclase Cardiovascular Disease
    SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .
    SGC agonist 2
  • HY-B1294R
    Amrinone (Standard)

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Amrinone (Standard) is the analytical standard of Amrinone. This product is intended for research and analytical applications. Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent .
    Amrinone (Standard)
  • HY-B1294
    Amrinone

    Inamrinone

    		 Phosphodiesterase (PDE) Cardiovascular Disease
    Amrinone (Inamrinone) is a positive inotropic-vasodilator agent. Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent .
    Amrinone
  • HY-16256
    Amrinone lactate

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Amrinone lactate is a positive inotropic-vasodilator agent. Amrinone lactate is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. Amrinone lactate is also an orally active, non-glycosidic and non-catecholamine cardiotonic agent .
    Amrinone lactate
  • HY-B1194R
    Tetramisole hydrochloride (Standard)

    (±)-Tetramisole hydrochloride (Standard); DL-Tetramisole hydrochloride (Standard); R-829 (Standard)

    		 Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole hydrochloride (Standard) is the analytical standard of Tetramisole (hydrochloride). This product is intended for research and analytical applications. Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole hydrochloride (Standard)
  • HY-B1639
    Enoximone

    		Phosphodiesterase (PDE) Cardiovascular Disease Inflammation/Immunology
    Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects .
    Enoximone
  • HY-117181
    UK-1745

    		Phosphodiesterase (PDE) Adrenergic Receptor Cardiovascular Disease
    UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .
    UK-1745
  • HY-18347
    Conivaptan

    YM 087 free base

    		 Vasopressin Receptor Cardiovascular Disease
    Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function .
    Conivaptan
  • HY-N0107R
    Cyclovirobuxine D (Standard)

    		Apoptosis Autophagy mTOR Akt Cardiovascular Disease
    Cyclovirobuxine D (Standard) is the analytical standard of Cyclovirobuxine D. This product is intended for research and analytical applications. Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces autophagy and attenuates the phosphorylation of Akt and mTOR . Cyclovirobuxine D inhibits cell proliferation of gastric cancer cells through suppression of cell cycle progression and inducement of mitochondria-mediated apoptosis . Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction .
    Cyclovirobuxine D (Standard)
  • HY-163120
    Myosin-IN-1

    		Myosin Cardiovascular Disease
    Myosin-IN-1 (compound F10) is a Myosin inhibitor that specifically targets cardiac myosin. Myosin-IN-1 stabilizes the biochemical and structural closed state of the cardiac myosin motor domain and reduces myocardial force production and calcium sensitivity in vitro. Myosin-IN-1 acts as a negative inotropic agent in isolated Langendroff-perfused rat hearts, reducing stress in isolated myofilaments and left ventricular pressure development. Myosin-IN-1 can be used in heart failure research .
    Myosin-IN-1
  • HY-P3211
    Nangibotide

    LR12

    		 TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis Cardiovascular Disease Inflammation/Immunology
    Nangibotide (LR12) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide inhibits Apoptosis. Nangibotide reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
    Nangibotide
  • HY-P0125B
    Elamipretide triacetate
    Maximum Cited Publications
    12 Publications Verification

    MTP-131 triacetate; RX-31 triacetate; SS-31 triacetate

    		 Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Elamipretide triacetate (MTP-131 triacetate; RX-31 triacetate; SS-31 triacetate) is Elamipretide triacetate form of Elamipretide (HY-P0125). Elamipretide triacetate is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury .
    Elamipretide triacetate
  • HY-122537
    Arotinolol hydrochloride

    		Adrenergic Receptor 5-HT Receptor Cardiovascular Disease
    Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
    Arotinolol hydrochloride
  • HY-P0125
    Elamipretide
    Maximum Cited Publications
    12 Publications Verification

    MTP-131; RX-31; SS-31

    		 Mitochondrial Metabolism Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Elamipretide (MTP-131) is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury .
    Elamipretide
  • HY-P3868A
    QEQLERALNSS TFA

    		Apoptosis Cardiovascular Disease
    QEQLERALNSS TFA is a helix B surface peptide (HBSP) derived from erythropoietin with tissue protective activities. QEQLERALNSS TFA protects cardiomyocytes from apoptosis .
    QEQLERALNSS TFA
  • HY-122537A
    Arotinolol

    		Adrenergic Receptor 5-HT Receptor Cardiovascular Disease
    Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .
    Arotinolol
  • HY-P3211A
    Nangibotide TFA
    3 Publications Verification

    LR12 TFA

    		 TREM receptor NF-κB NOD-like Receptor (NLR) Interleukin Related Apoptosis Cardiovascular Disease Inflammation/Immunology
    Nangibotide TFA (LR12 TFA) is a synthetic peptide and TREM-1 receptor inhibitor. Nangibotide TFA inhibits NF-κB and NLRP3 inflammasome activation and reduces the release of pro-inflammatory factors (such as IL-1β, IL-8). Nangibotide TFA inhibits Apoptosis. Nangibotide TFA reduces excessive inflammatory responses and protects tissues (liver, lung) from damage. Nangibotide TFA can be used in the researches for myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure .
    Nangibotide TFA
  • HY-162729
    LSD1-IN-34

    		Histone Demethylase Monoamine Oxidase TGF-beta/Smad Cardiovascular Disease
    LSD1-IN-34 (Compound 7d) is the orally active inhibitor for Lysine-specific demethylase (LSD) and monoamine oxidase (MAO), with IC50 of 4.51 and 18.46 nM, for LSD1 and MAO A. LSD1-IN-34 inhibits the Ang II-induced neonatal rat myocardial fibroblasts (NRCFs) activation, without significant toxicity (20 μM). LSD1-IN-34 inhibits TGFβ/Smad signaling pathway, and ameliorates heart failure in mice. LSD1-IN-34 exhibits good pharmacokinetic characteristics in rats .
    LSD1-IN-34
  • HY-158426
    2-APQC

    		Sirtuin Cardiovascular Disease
    2-APQC is a SIRT3 activator with the Kd value of 2.756 μM. 2-APQC improves heart failure in vitro and in vivo .
    2-APQC
  • HY-10397A
    MX1013
    2 Publications Verification

    CV1013; Z-VD-FMK

    		 Caspase Cancer
    MX1013 is a potent, irreversible dipeptide caspase inhibitor vith antiapoptotic activity. MX1013 inhibits recombinant human caspase 3 with an IC50 of 30 nM .
    MX1013
  • HY-121705
    Propionyl-L-carnitine

    		Endogenous Metabolite Apoptosis Bcl-2 Family NF-κB Survivin Src Akt AMPK NO Synthase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis .
    Propionyl-L-carnitine
  • HY-14299D
    Indacaterol acetate

    		Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research .
    Indacaterol acetate
  • HY-14299
    Indacaterol
    4 Publications Verification

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
    Indacaterol
  • HY-14299A
    Indacaterol maleate
    4 Publications Verification

    QAB149

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
    Indacaterol maleate
  • HY-14299AR
    Indacaterol (maleate) (Standard)

    		Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
    Indacaterol (maleate) (Standard)
  • HY-14299R
    Indacaterol (Standard)

    		Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
    Indacaterol (Standard)
  • HY-100408
    GNF-6231

    		Wnt Porcupine Cardiovascular Disease Cancer
    GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction .
    GNF-6231
  • HY-106994
    Nebentan

    YM598 free base

    		 Endothelin Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ 125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .
    Nebentan